Dexmedetomidine-containing patient-controlled intravenous analgesia after elective caesarean delivery: a retrospective cohort study.
- 1Department of Anesthesiology, Yongkang Women and Children's Health Hospital, Yongkang, Zhejiang, China.
- 2Department of Laboratory Medicine, Yongkang Women and Children's Health Hospital, Yongkang, Zhejiang, China.
- 3Department of Obstetrics, Yongkang Women and Children's Health Hospital, Yongkang, Zhejiang, China.
Abstract
Dexmedetomidine is used as an adjunct in multimodal postoperative analgesia, but evidence from routine clinical care after caesarean delivery remains limited. We evaluated whether dexmedetomidine-containing patient-controlled intravenous analgesia (PCIA) was associated with postoperative analgesic and early recovery outcomes. This single-centre retrospective cohort study included women aged 18-45 years undergoing elective term caesarean delivery between January and September 2025. Women were classified according to the initial postoperative PCIA regimen as receiving dexmedetomidine-containing or conventional PCIA. The primary outcome was movement pain on a 0-10 numerical rating scale at 24 h. Secondary outcomes included pain through 48 h, sufentanil delivery, patient-controlled analgesia demands, rescue analgesia, treatment-related events, and early recovery milestones. Propensity-score overlap weighting was used for the primary analysis. Propensity-score matching, conventional multivariable adjustment, complete-case and restricted-cohort analyses, and an expanded propensity-score model incorporating attending anaesthesiologist and calendar month were used to assess robustness. Among 304 eligible women, 132 received dexmedetomidine-containing PCIA and 172 received conventional PCIA. Mean movement pain at 24 h was 3.1 (SD 1.2) versus 3.7 (SD 1.3), corresponding to an overlap-weighted mean difference of -0.51 points (95% CI -0.80 to -0.22; P < 0.001). The primary estimate was similar across sensitivity analyses, including the expanded propensity-score model incorporating attending anaesthesiologist and calendar month. Among 290 women with complete 48-h pump records, median cumulative sufentanil delivery was 84 μg (IQR 78-91) versus 90 μg (82-98; median difference -5.2 μg, 95% CI -7.8 to -2.6; P < 0.001). Rescue analgesia was required in 24 of 132 women (18.2%) versus 46 of 172 (26.7%; risk ratio 0.72, 95% CI 0.52-0.99; P = 0.044). First mobilisation occurred at 16.9 versus 19.3 h (time ratio 0.89, 95% CI 0.84-0.95; P < 0.001), and first passage of flatus at 25.8 versus 28.9 h (time ratio 0.92, 95% CI 0.86-0.98; P = 0.012). Estimates for uncommon adverse events were imprecise. In this retrospective cohort, dexmedetomidine-containing PCIA was associated with modestly lower early movement pain and lower analgesic requirements, with shorter observed times to selected early recovery milestones. Estimates for uncommon adverse events did not establish safety equivalence. These observational findings should not be interpreted as establishing a causal treatment effect.
Related
- Combined Pectoral Nerve Block and Intravenous Dexmedetomidine in Contemporary Multimodal Breast Cancer Analgesia: A Real-World Cohort Study
- Intraoperative intravenous lidocaine for analgesia after oral cancer surgery with free perforator flap reconstruction: a randomised controlled trial
- Haemodynamic and Respiratory Effects of Dexmedetomidine as an Adjuvant to Oxycodone Patient‐Controlled Analgesia After Lumbar Spinal Fusion: A Post Hoc Analysis of the DoseRespDex Randomised Controlled Trial
- Effects of different doses of esketamine as an adjunct to sufentanil-based patient-controlled intravenous analgesia on postoperative analgesia and opioid consumption following lumbar decompression surgery: a dose-finding randomized controlled trial
- Effect of Adding Esketamine to Patient-Controlled Intravenous Analgesia on Rebound Pain After Interscalene Brachial Plexus Block: A Randomized Controlled Trial
BibTeX
@article{lu2026dexmedetomidinecontaining,
title = {{Dexmedetomidine-containing patient-controlled intravenous analgesia after elective caesarean delivery: a retrospective cohort study.}},
author = {YinJun Lu and YuHui Huang and ChaoRen Hu and Li Ying and ShuCan Quan and Lei Li and Xiongying Li and YingLi Cheng},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1991923},
url = {https://europepmc.org/article/MED/42952944},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dexmedetomidine-containing patient-controlled intravenous analgesia after elective caesarean delivery: a retrospective cohort study.
AU - YinJun Lu
AU - YuHui Huang
AU - ChaoRen Hu
AU - Li Ying
AU - ShuCan Quan
AU - Lei Li
AU - Xiongying Li
AU - YingLi Cheng
PY - 2026
DA - 2026/10/14
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1991923
UR - https://europepmc.org/article/MED/42952944
AB - Dexmedetomidine is used as an adjunct in multimodal postoperative analgesia, but evidence from routine clinical care after caesarean delivery remains limited. We evaluated whether dexmedetomidine-containing patient-controlled intravenous analgesia (PCIA) was associated with postoperative analgesic and early recovery outcomes. This single-centre retrospective cohort study included women aged 18-45 years undergoing elective term caesarean delivery between January and September 2025. Women were classified according to the initial postoperative PCIA regimen as receiving dexmedetomidine-containing or conventional PCIA. The primary outcome was movement pain on a 0-10 numerical rating scale at 24 h. Secondary outcomes included pain through 48 h, sufentanil delivery, patient-controlled analgesia demands, rescue analgesia, treatment-related events, and early recovery milestones. Propensity-score overlap weighting was used for the primary analysis. Propensity-score matching, conventional multivariable adjustment, complete-case and restricted-cohort analyses, and an expanded propensity-score model incorporating attending anaesthesiologist and calendar month were used to assess robustness. Among 304 eligible women, 132 received dexmedetomidine-containing PCIA and 172 received conventional PCIA. Mean movement pain at 24 h was 3.1 (SD 1.2) versus 3.7 (SD 1.3), corresponding to an overlap-weighted mean difference of -0.51 points (95% CI -0.80 to -0.22; P < 0.001). The primary estimate was similar across sensitivity analyses, including the expanded propensity-score model incorporating attending anaesthesiologist and calendar month. Among 290 women with complete 48-h pump records, median cumulative sufentanil delivery was 84 μg (IQR 78-91) versus 90 μg (82-98; median difference -5.2 μg, 95% CI -7.8 to -2.6; P < 0.001). Rescue analgesia was required in 24 of 132 women (18.2%) versus 46 of 172 (26.7%; risk ratio 0.72, 95% CI 0.52-0.99; P = 0.044). First mobilisation occurred at 16.9 versus 19.3 h (time ratio 0.89, 95% CI 0.84-0.95; P < 0.001), and first passage of flatus at 25.8 versus 28.9 h (time ratio 0.92, 95% CI 0.86-0.98; P = 0.012). Estimates for uncommon adverse events were imprecise. In this retrospective cohort, dexmedetomidine-containing PCIA was associated with modestly lower early movement pain and lower analgesic requirements, with shorter observed times to selected early recovery milestones. Estimates for uncommon adverse events did not establish safety equivalence. These observational findings should not be interpreted as establishing a causal treatment effect.
SN - 2296-858X
ER -